Urine has become one of the most attractive biofluids in clinical proteomics as it can be
obtained non-invasively in large quantities and is stable compared with other biofluids. The …

Mass spectrometry platforms have attracted a lot of interest in the last 2 decades as profiling
tools for native peptides and proteins with clinical potential. However, limitations associated …

Because of its availability, ease of collection, and correlation with physiology and pathology,
urine is an attractive source for clinical proteomics/peptidomics. However, the lack of …

Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or
the presence of significant albuminuria. With the aim of early and improved risk stratification …

Diabetic nephropathy (DN) is a progressive kidney disease, a well-known complication of
long-standing diabetes. DN is the most frequent reason for dialysis in many Western …

Background Non-invasive methods for diagnosis of urothelial carcinoma have reduced
specificity in patients with non-malignant genitourinary disease or other disorders. We aimed …

Capillary electrophoresis combined with mass spectrometry (CE‐MS) has been used for
several years for the investigation of proteins and peptides as biomarkers for diagnosis and …

A limitation of proteomic methods with respect to their clinical applicability is the lack of
possibilities to directly deduce the amount of a protein or peptide from a particular mass …

Proteome analysis is now emerging as key technology for deciphering biological processes
and the discovery of biomarkers for diseases from tissues and body fluids. The complexity …

Noninvasive diagnosis of kidney diseases and assessment of the prognosis are still
challenges in clinical nephrology. Definition of biomarkers on the basis of proteome …